Search - tctmd.com

Displaying 1 - 20 of 58

Sort: Relevancy | Date

Presentation TCT 2019

BIOFREEDOM: The LEADERS FREE Program and Beyond

Presenter: Philip Urban

September 28, 2019

Presentation TCT 2019

Defining High Bleeding Risk: HBR ARC

Presenter: Philip Urban

September 27, 2019

Presentation TCT 2019

Idenifying the High Bleeding Risk Patient: The ARC HBR Definitions

Presenter: Philip Urban

September 27, 2019

Presentation TCT 2018

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Philip M. Urban

September 23, 2018

Presentation TCT 2018

Case Conclusion

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Presenter: Philip M. Urban, Robert W. Yeh, Stephan Windecker

September 22, 2018

Presentation TCT 2018

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Presenter: Philip M. Urban, Robert W. Yeh, C. Michael Gibson

September 22, 2018

Presentation TCT 2018

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

Presenter: Philip M. Urban, Robert W. Yeh, Tullio Palmerini

September 22, 2018

Presentation TCT 2017

BioFreedom: LEADERS FREE Long-term Results and LEADERS FREE II Design

Presenter: Mitchell W. Krucoff, Chaim S. Lotan, Philip M. Urban

November 01, 2017

Presentation TCT 2017

Controversial Position Statement: Polymer-Free DES Provide the Optimal Balance of Safety and Efficacy (and Will Improve Most in the Future)!

Presenter: Giulio G. Stefanini, Stephan Windecker, Philip M. Urban

October 30, 2017

Presentation TCT 2016

Highlights (and my Interpretations) From: PLATINUM DIVERSITY

Presenter: Philip M. Urban, Stephen G. Worthley, Bonnie H. Weiner

November 01, 2016

Presentation TCT 2016

Highlights (and My Interpretations) From: Absorb BVS - ABSORB II and ABSORB China (2-3 Year Results)

Presenter: Philip M. Urban, Stephen G. Worthley, Stephen G. Ellis

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: New BRS - FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6-9 Month Results)

Presenter: Philip M. Urban, Stephen G. Worthley, Robert-Jan van Geuns

November 01, 2016

Presentation TCT 2016

Highlights (And my Interpretations) From: Polymer-free DES - LEADERS-free 2-year and RevElution

Presenter: Philip M. Urban, Stephen G. Worthley, Christian M. Spaulding

November 01, 2016

Presentation TCT 2016

Highlights (And my Interpretations) From: DES Comparisons BIO-RESORT (TWENTE III) and BIONICS

Presenter: Philip M. Urban, Stephen G. Worthley, Sigmund Silber

November 01, 2016

Presentation TCT 2016

Trial #3 - The Essentials of ... the LEADERS FREE trial

Presenter: Sunil V. Rao, Harvey D. White, Philip M. Urban

October 31, 2016

Presentation TCT 2016

Biosensors Biofreedom/Cordis Lumeno: Angiographic/Clinical Outcomes And Further Worldwide Development Strategy

Presenter: Marie-Claude Morice, Philip M. Urban

October 31, 2016

Presentation TCT 2016

LEADERS FREE: Two-Year Clinical and Subgroup Outcomes From a Prospective, Randomized Trial of a Polymer-Free Drug-Coated Stent and a Bare Metal Stent in Patients With Coronary Artery Disease at High Bleeding Risk

Presenter: David W.M. Muller, Jonathan M. Hill, Philip M. Urban

October 30, 2016

Advertisement

BIOFREEDOM: The LEADERS FREE Program and Beyond

Defining High Bleeding Risk: HBR ARC

Idenifying the High Bleeding Risk Patient: The ARC HBR Definitions

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Case Conclusion

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

BioFreedom: LEADERS FREE Long-term Results and LEADERS FREE II Design

Controversial Position Statement: Polymer-Free DES Provide the Optimal Balance of Safety and Efficacy (and Will Improve Most in the Future)!

Highlights (and my Interpretations) From: PLATINUM DIVERSITY

Highlights (and My Interpretations) From: Absorb BVS - ABSORB II and ABSORB China (2-3 Year Results)

Highlights (and my Interpretations) From: New BRS - FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6-9 Month Results)

Highlights (And my Interpretations) From: Polymer-free DES - LEADERS-free 2-year and RevElution

Highlights (And my Interpretations) From: DES Comparisons BIO-RESORT (TWENTE III) and BIONICS

Trial #3 - The Essentials of ... the LEADERS FREE trial

Biosensors Biofreedom/Cordis Lumeno: Angiographic/Clinical Outcomes And Further Worldwide Development Strategy

LEADERS FREE: Two-Year Clinical and Subgroup Outcomes From a Prospective, Randomized Trial of a Polymer-Free Drug-Coated Stent and a Bare Metal Stent in Patients With Coronary Artery Disease at High Bleeding Risk

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content